Sugi Predict

Sugi Predict / Compounds / SCHEMBL2236935

SCHEMBL2236935

SCHEMBL2236935

CC(C)NCC[C@H](N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 3/20 0.46
▸ SLC1A2 P43004 3/20 0.46
▸ SLC1A1 P43005 3/20 0.46
▸ GSR P00390 2/20 0.46
▸ SLC7A5 Q01650 1/20 0.46
▸ GRM8 O00222 1/20 0.46
▸ GRM6 O15303 1/20 0.46
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ GRIK1 P39086 1/20 0.46
▸ GRM5 P41594 1/20 0.46
▸ GRIA1 P42261 1/20 0.46
▸ GRIA2 P42262 1/20 0.46
▸ GRIA3 P42263 1/20 0.46
▸ GRIA4 P48058 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIK2 Q13002 1/20 0.46
▸ GRIK3 Q13003 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236943 1.00 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1GSRSLC7A5
SCHEMBL25406097 1.00 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1GSRSLC7A5
SCHEMBL14844417 0.88 GSR (0.50) SLC1A3SLC1A2SLC1A1GSRSLC7A5
SCHEMBL18741586 0.88 GSR (0.50) SLC1A3SLC1A2SLC1A1GSRSLC7A5
SCHEMBL8709636 0.88 GSR (0.50) SLC1A3SLC1A2SLC1A1GSRSLC7A5
SCHEMBL457067 0.86 GSR (0.53) GSRCYP1A2BLMKMT2A
SCHEMBL1932144 0.86 GSR (0.53) GSRCYP1A2BLMKMT2A
SCHEMBL3727819 0.86 GSR (0.53) GSRCYP1A2BLMKMT2A
SCHEMBL10125779 0.83 ANPEP (0.35) SLC1A3SLC1A2SLC1A1SLC7A5
SCHEMBL12438071 0.81 GABRP (0.35) SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042800-A1 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) 2026-02-12 — — US claimed
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 — — US claimed
US-20240228555-A9 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-07-11 — — US claimed
EP-4380689-A1 ANTIMICROBIAL PEPTIDOMIMETICS Basilea Pharmaceutica International AG, Allschwil (CH) 2024-06-12 — — EP claimed
CN-118043339-A Antimicrobial peptidomimetics 巴斯利尔药物阿尔施维尔国际股份公司 2024-05-14 — — CN claimed
US-20240132553-A1 ANTIMICROBIAL PEPTIDOMIMETICS SPEXIS AG (CH) 2024-04-25 — — US claimed
US-20240082346-A1 Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2024-03-14 — — US claimed
US-11883501-B2 Selective CXCR4 binding peptide conjugate and methods for making and using the same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2024-01-30 — — US claimed
US-11771736-B2 Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2023-10-03 — — US claimed
EP-4214220-A1 ANTIMICROBIAL PEPTIDOMIMETICS Spexis AG (CH) 2023-07-26 — — EP claimed
CN-115989236-A Antimicrobial peptidomimetics 斯派西斯公司 2023-04-18 — — CN claimed
WO-2023012319-A1 ANTIMICROBIAL PEPTIDOMIMETICS SPEXIS AG (CH) 2023-02-09 — — WO claimed
EP-4097120-A1 ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME Mainline Biosciences LLC (US) 2022-12-07 — — EP claimed
WO-2022028737-A1 ANTIMICROBIAL PEPTIDOMIMETICS POLYPHOR AG (CH) 2022-02-10 — — WO claimed
US-20260042800-A1 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) 2026-02-12 — — US disclosed
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 — — US disclosed
US-20240228555-A9 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-07-11 — — US disclosed
US-20100016238-A1 Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
WO-2008087186-A2 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed
WO-2008087187-A1 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883501-B2 Selective CXCR4 binding peptide conjugate and methods for making and using the same CXCR4, CXCR1, ACKR3 SLC1A3 112/4885SLC1A2 493/4885SLC1A1 126/4885
US-20100016238-A1 Peptides for Use in the Treatment of Obesity MC4R, GIPR, MC3R SLC1A3 895/4885SLC1A2 1510/4885SLC1A1 847/4885
US-20260042800-A1 ANTIMICROBIAL PEPTIDOMIMETICS CUTA, NGLY1, P4HB SLC1A3 1789/4885SLC1A2 3386/4885SLC1A1 1632/4885
US-11771736-B2 Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same CXCR4, CXCR3, CXCR1 SLC1A3 1933/4885SLC1A2 1973/4885SLC1A1 1321/4885
US-20240082346-A1 Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same CXCR4, CXCR3, CXCR1 SLC1A3 1899/4885SLC1A2 1928/4885SLC1A1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.